Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.

Kuykendall AT, Padron E.

Curr Hematol Malig Rep. 2019 Dec;14(6):543-549. doi: 10.1007/s11899-019-00553-5. Review.

PMID:
31776774
2.

Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.

Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS.

Am J Hematol. 2019 Dec;94(12):E314-E317. doi: 10.1002/ajh.25625. Epub 2019 Sep 10. No abstract available.

PMID:
31444809
3.

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.

Talati C, Dhulipala VC, Extermann MT, Ali NA, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE.

Haematologica. 2020 Jan 31;105(2):398-406. doi: 10.3324/haematol.2018.208637. Print 2020.

4.

Leading for research excellence and integrity: A qualitative investigation of the relationship-building practices of exemplary principal investigators.

Antes AL, Kuykendall A, DuBois JM.

Account Res. 2019 Apr;26(3):198-226. doi: 10.1080/08989621.2019.1611429. Epub 2019 May 14.

PMID:
31033345
5.

The lab management practices of "Research Exemplars" that foster research rigor and regulatory compliance: A qualitative study of successful principal investigators.

Antes AL, Kuykendall A, DuBois JM.

PLoS One. 2019 Apr 24;14(4):e0214595. doi: 10.1371/journal.pone.0214595. eCollection 2019.

6.

Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6.

PMID:
30625392
7.

Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.

Kuykendall AT, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS.

Am J Hematol. 2019 Jan;94(1):87-92. doi: 10.1002/ajh.25335. Epub 2018 Nov 25.

8.

Acute Myeloid Leukemia: The Good, the Bad, and the Ugly.

Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:555-573. doi: 10.1200/EDBK_199519. Review.

9.

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30.

PMID:
29189896
10.

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. doi: 10.1016/j.clml.2017.08.002. Epub 2017 Aug 5.

PMID:
28869184
11.

Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.

Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E.

Blood. 2017 Mar 30;129(13):1881-1883. doi: 10.1182/blood-2016-12-753210. Epub 2017 Feb 3. No abstract available.

PMID:
28159734
12.
13.

Parkinsonian tremor: soe aspects of an experimental model and its solution.

Austin G, Hayward W, Tsai C, Kuykendall A.

Confin Neurol. 1965;26(3):389-403. No abstract available.

PMID:
5329843

Supplemental Content

Loading ...
Support Center